Download Files:
Products Details
Product Description
– NLRP3-IN-8 (compound 27) is an orally active, directly binding NLRP3 inflammasome inhibitor with an IC50 value of 1.23 μM against IL-1 β. NLRP3-IN-8 has good metabolic stability to liver microsomes (t1/2 = 138.63 min), and has almost no toxicity (against L02: IC50 > 100 μM)[1].
Web ID
– HY-146594
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C23H20N2O6
References
– [1]Xing Xing Zhang, et al. Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis. Eur J Med Chem. 2022 Apr 7;236:114357.
CAS Number
– 2768650-56-0
Molecular Weight
– 420.41
SMILES
– COC1=CC(OC)=C(C(/C=C/C2=CC=C(C=C2)NC(C3=CC=CO3)=O)=C1)/C=C/[N+]([O-])=O
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– NOD-like Receptor (NLR)
Isoform
– NLRP3
Pathway
– Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
